146 related articles for article (PubMed ID: 9530527)
1. Evaluation of the developmental toxicities of coumarin, 4-hydroxycoumarin, and 7-hydroxycoumarin using FETAX.
Fort DJ; Stover EL; Propst T; Hull MA; Bantle JA
Drug Chem Toxicol; 1998 Feb; 21(1):15-26. PubMed ID: 9530527
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the developmental toxicity of theophylline, dimethyluric acid, and methylxanthine metabolites using Xenopus.
Fort DJ; Stover EL; Propst T; Hull MA; Bantle JA
Drug Chem Toxicol; 1996 Nov; 19(4):267-78. PubMed ID: 8972234
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the developmental toxicity of benzo[a]pyrene and 2-acetylaminofluorene using Xenopus: modes of biotransformation. Stover Group.
Propst TL; Fort DJ; Stover EL; Schrock B; Bantle JA
Drug Chem Toxicol; 1997; 20(1-2):45-61. PubMed ID: 9183562
[TBL] [Abstract][Full Text] [Related]
4. Optimization of an exogenous metabolic activation system for FETAX. I. Post-isolation rat liver microsome mixtures.
Fort DJ; Rogers RL; Stover EL; Finch RA
Drug Chem Toxicol; 2001 May; 24(2):103-15. PubMed ID: 11360429
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the developmental toxicity of 4-bromobenzene using frog embryo teratogenesis assay--Xenopus: possible mechanisms of action.
Fort DJ; Propst TL; Stover EL
Teratog Carcinog Mutagen; 1996; 16(6):307-15. PubMed ID: 9178453
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of acetaminophen-induced developmental toxicity using FETAX.
Fort DJ; Rayburn JR; Bantle JA
Drug Chem Toxicol; 1992; 15(4):329-50. PubMed ID: 1459044
[TBL] [Abstract][Full Text] [Related]
7. Use of Frog Embryo Teratogenesis Assay-Xenopus and an exogenous metabolic activation system to evaluate the developmental toxicity of diphenylhydantoin.
Fort DJ; Bantle JA
Fundam Appl Toxicol; 1990 May; 14(4):720-33. PubMed ID: 2361573
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the developmental toxicity of caffeine and caffeine metabolites using the frog embryo teratogenesis assay--Xenopus (FETAX).
Fort DJ; Stover EL; Propst TL; Faulkner BC; Vollmuth TA; Murray FJ
Food Chem Toxicol; 1998 Jul; 36(7):591-600. PubMed ID: 9687966
[TBL] [Abstract][Full Text] [Related]
9. Phase III interlaboratory study of FETAX, Part 2: interlaboratory validation of an exogenous metabolic activation system for frog embryo teratogenesis assay--Xenopus (FETAX).
Fort DJ; Stover EL; Bantle JA; Rayburn JR; Hull MA; Finch RA; Burton DT; Turley SD; Dawson DA; Linder G; Buchwalter D; Dumont JN; Kumsher-King M; Gaudet-Hull AM
Drug Chem Toxicol; 1998 Feb; 21(1):1-14. PubMed ID: 9530526
[TBL] [Abstract][Full Text] [Related]
10. Biotransformation of coumarin by rodent and human cytochromes P-450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice.
Zhuo X; Gu J; Zhang QY; Spink DC; Kaminsky LS; Ding X
J Pharmacol Exp Ther; 1999 Feb; 288(2):463-71. PubMed ID: 9918546
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the developmental toxicity of trichloroethylene and detoxification metabolites using Xenopus.
Fort DJ; Stover EL; Rayburn JR; Hull M; Bantle JA
Teratog Carcinog Mutagen; 1993; 13(1):35-45. PubMed ID: 8100651
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the developmental toxicity of thalidomide using frog embryo teratogenesis assay-xenopus (FETAX): biotransformation and detoxification.
Fort DJ; Stover EL; Bantle JA; Finch RA
Teratog Carcinog Mutagen; 2000; 20(1):35-47. PubMed ID: 10607376
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of prostaglandin biosynthesis by coumarin, 4-hydroxycoumarin, and 7-hydroxycoumarin.
Lee RE; Bykadi G; Ritschel WA
Arzneimittelforschung; 1981; 31(4):640-2. PubMed ID: 7195710
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and toxicity of coumarin on cultured human, rat, mouse and rabbit hepatocytes.
Ratanasavanh D; Lamiable D; Biour M; Guédès Y; Gersberg M; Leutenegger E; Riché C
Fundam Clin Pharmacol; 1996; 10(6):504-10. PubMed ID: 8985719
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of coumarin by rat, gerbil and human liver microsomes.
Fentem JH; Fry JR
Xenobiotica; 1992 Mar; 22(3):357-67. PubMed ID: 1496825
[TBL] [Abstract][Full Text] [Related]
16. Assessing the efficacy of an Aroclor 1254-induced exogenous metabolic activation system for FETAX.
Fort DJ; Rayburn JR; DeYoung DJ; Bantle JA
Drug Chem Toxicol; 1991; 14(1-2):143-60. PubMed ID: 1889373
[TBL] [Abstract][Full Text] [Related]
17. o-hydroxyphenylacetaldehyde is a hepatotoxic metabolite of coumarin.
Born SL; Hu JK; Lehman-McKeeman LD
Drug Metab Dispos; 2000 Feb; 28(2):218-23. PubMed ID: 10640521
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the developmental toxicities of ethanol, acetaldehyde, and thioacetamide using FETAX.
Fort DJ; McLaughlin DW; Rogers RL; Buzzard BO
Drug Chem Toxicol; 2003 Feb; 26(1):23-34. PubMed ID: 12643038
[TBL] [Abstract][Full Text] [Related]
19. Studies on the mechanism of coumarin-induced toxicity in rat hepatocytes: comparison with dihydrocoumarin and other coumarin metabolites.
Lake BG; Gray TJ; Evans JG; Lewis DF; Beamand JA; Hue KL
Toxicol Appl Pharmacol; 1989 Feb; 97(2):311-23. PubMed ID: 2922762
[TBL] [Abstract][Full Text] [Related]
20. Optimization of an exogenous metabolic activation system for FETAX. II. Preliminary evaluation.
Fort DJ; Rogers RL; Paul RR; Stover EL; Finch RA
Drug Chem Toxicol; 2001 May; 24(2):117-27. PubMed ID: 11360430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
